


Date	Nifty Spot	Nifty Future	Pre / Dis	Nifty Future Curr. expiry OI	Nifty Future Total OI	PCR (OI)	VIX	Most Active Call	Most Active Put	P/E	Nifty P/B
22-Nov	10342	10,358	15.65	21,734,175	25,369,350	0.97	14.04	10300	10100	26.40	3.48
21-Nov	10327	10,352	25.00	22,165,500	25,356,000	0.97	13.72	10300	10300	26.20	3.48
<b>Chg</b>	<b>0.15%</b>	<b>0.06%</b>		<b>-1.95%</b>	<b>0.05%</b>		<b>2.35%</b>				


Nifty Options Data is for the expiry 30-Nov-17



### NIFTY PREMIUM / DISCOUNT



### CNX NIFTY vs INDIA VIX



### MARKET OVERVIEW

The India Volatility Index (VIX), a gauge for market's short term expectation of volatility increased by 2.35% and reached 14.04.

Nifty November 2017 futures closed at 10357.95 on Wednesday, at a premium of 15.65 points over spot closing of 10342.30,

Nifty December 2017 futures ended at 10393.90, at a premium of 51.60 points over spot closing.

Nifty November futures saw a contraction of 0.43 million (mn) units, taking the total outstanding open interest (OI) to 21.73 mn units.

The Nifty Put Call Ratio (PCR) finally stood at 0.97 for November month contract.

The top five scrips with highest PCR on OI were Godrej Consumer Products (3.72), JSW Energy (2.23), DLF (1.35), Dewan Housing Finance Corporation (1.35) and Maruti Suzuki India (1.36).

From the most active contracts, State Bank of India November 2017 futures traded at a premium of 0.45 point at 335.95 compared with spot closing of 335.50. The numbers of contracts traded were 24,957.

Tata Motors November 2017 futures traded at a premium of 1.70 points at 429.70 compared with spot closing of 428.00. The numbers of contracts traded were 17,481.

Sun Pharmaceutical Industries November 2017 futures traded at a premium of 0.15 points at 537.15 compared with spot closing of 537.00. The numbers of contracts traded were 14,895.

Punjab National Bank November 2017 futures traded at a premium of 0.90 points at 189.70 compared with spot closing of 188.80. The numbers of contracts traded were 13,551.

Bank of Baroda November 2017 futures traded at a premium of 0.60 points at 181.20 compared with spot closing of 180.60. The numbers of contracts traded were 10,499.

**Nifty Call Options**


Strike	Nifty Call OI	Chg in OI	Curr. IV	Prev. IV	LTP	Net Chg
9900	537,900	-5625	-	13	461	7.7
10000	633,900	-13950	9	15	359	3.3
10100	625,200	-33375	9	11	266	1.1
10200	1,299,375	-170625	11	11	178	2.0
10300	2,994,000	-349125	10	11	101	-0.3
10400	5,237,325	237225	10	11	48	-3.2
10500	6,133,425	-30075	10.7	11.2	19.9	-2.7
10600	4,133,625	136650	11.1	11.4	7.2	-1.5
10700	2,705,850	-89025	11.9	12.3	2.7	-0.9
10800	2,258,025	-146250	13.2	13.5	1.4	-0.6

**Nifty Put Options**

Strike	Nifty Put OI	Chg in OI	Curr. IV	Prev. IV	LTP	Net Chg
9900	2,393,400	59775	-	16	3.0	-0.7
10000	4,947,000	-81525	9	15	5.6	-1.2
10100	3,238,200	255150	9	13	10.6	-2.1
10200	4,676,400	-227475	11	12	21.5	-3.5
10300	5,437,275	43425	10	11	44	-5.5
10400	1,826,175	195300	10	11	88	-8.0
10500	676,575	-4725	10.7	10.4	157	-7.1
10600	380,700	-21750	11.1	9.6	243	-6.2
10700	225,075	-42750	11.9	-	334	-8.4
10800	36,600	0	13.2	14.9	437	-13.3

Nifty Options Data is for the expiry 30-Nov-17

**OPEN INTEREST – NIFTY CALL & NIFTY PUT**




Nifty calls, 10300 SP from the November month expiry was the most active call with a contraction of 0.35 million open interests.


Nifty puts, 10100 SP from the November month expiry was the most active put with a contraction of 0.26 million open interests.

The maximum OI outstanding for Calls was at 10500 SP (6.13 mn) and that for Puts was at 10300 SP (5.44 mn).

**OI PCR, OI Value PCR vs NIFTY FUTURES**



**Change in OPEN INTEREST (Total) vs NIFTY FUTURES**



**NIFTY OPTIONS**
**Nifty Bullish Call Spread**

Action	Strike	Premium	Max Profit	Max Loss
Buy	10300	100.95	46.05	53.95
Sell	10400	47.00		
Buy	10400	47.00	72.35	27.65
Sell	10500	19.35		
Buy	10300	100.95	118.40	81.60
Sell	10500	19.35		

**Nifty Bearish Put Spread**

Action	Strike	Premium	Max Profit	Max Loss
Buy	10400	85.10	56.70	43.30
Sell	10300	41.80		
Buy	10300	41.80	77.75	22.25
Sell	10200	19.55		
Buy	10400	85.10	134.45	65.55
Sell	10200	19.55		

Note: Above spread are provided for information purposes.

**STOCK OPTIONS**
**Most Active Calls**

Scrip	Strike Price	Price	Spot	Turnover (Rs Crs.)	Expiry
SBIN	340	5.40	335	619	30-Nov-17
TATAMOTORS	440	4.70	429	292	30-Nov-17
MARUTI	8500	90.00	8513	278	30-Nov-17
TATAMOTORS	430	7.90	429	254	30-Nov-17
SBIN	350	2.95	335	406	30-Nov-17

**Most Active Puts**

Scrip	Strike Price	Price	Spot	Turnover (Rs Crs.)	Expiry
SBIN	330	4.25	335	393	30-Nov-17
SBIN	320	1.80	335	234	30-Nov-17
MARUTI	8400	40.80	8513	139	30-Nov-17
RELIANCE	920	8.05	931	197	30-Nov-17
RELIANCE	930	12.30	931	189	30-Nov-17

**STOCK FUTURES**
**LONG BUILDUP (Price rise OI rise)**

Stock	CMP	Price Chg	OI Chg	(NSE+BSE) %Delivery	Recovery
ZEEL	562	4.0%	17.8%	22%	4%
APOLLOHOSP	1150	3.8%	6.4%	45%	4%
UBL	1111	3.7%	0.3%	18%	4%
INDIACEM	176	3.4%	3.0%	25%	3%
RCOM	14	3.3%	2.6%	10%	3%

**SHORT BUILDUP (Price fall OI rise)**

Stock	CMP	Price chg	OI chg	(NSE+BSE) %Delivery	Fall from High
BIOCON	409	-2.5%	0.6%	31%	3%
IDEA	98	-2.4%	1.1%	29%	5%
BATAINDIA	749	-2.3%	20.8%	17%	6%
MOTHERSUMI	345	-2.3%	13.5%	69%	3%
BALRAMCHIN	160	-2.2%	1.0%	28%	3%

**SHORT UNWINDING (Price rise OI fall)**

Stock	CMP	Price Chg	OI Chg	(NSE+BSE) %Delivery	Recovery
ADANI PORTS	415	3.4%	-0.7%	42%	3%
JPASSOCIAT	19	2.7%	-1.3%	14%	8%
KSCL	563	2.5%	-4.4%	40%	4%
CUMMINSIND	868	2.1%	-6.8%	57%	2%
ORIENTBANK	130	1.8%	-1.3%	17%	4%

**LONG UNWINDING (Price fall OI fall)**

Stock	CMP	Price chg	OI chg	(NSE+BSE) %Delivery	Fall from High
WOCKPHARMA	720	-2.8%	-8.6%	21%	3%
PAGEIND	22514	-2.6%	-7.4%	40%	3%
TECHM	483	-2.3%	-0.5%	50%	3%
HDIL	61	-2.1%	-5.4%	22%	4%
JUSTDIAL	528	-1.7%	-4.4%	9%	3%

Long positions were witnessed in stocks like ZEEL & APOLLOHOSP

Short positions were witnessed in stocks like BIOCON & IDEA

### FII's ACTIVITY IN DERIVATIVES

22-Nov-17 Rs. Crs	Buy	Sell	Net	OI Value	% Chg	OI Contracts	% Chg
INDEX FUTURES	1,324	1,182	142	26,978	0.0%	334,371	-0.2%
INDEX OPTIONS	63,445	63,547	-102	98,887	1.8%	1,228,444	1.7%
<b>TOTAL INDEX</b>	<b>64,769</b>	<b>64,729</b>	<b>40</b>				
STOCK FUTURES	7,310	7,541	-231	71,930	0.0%	1,033,317	0.1%
STOCK OPTIONS	6,565	6,563	1	9,383	1.1%	131,610	0.9%
<b>TOTAL STOCKS</b>	<b>13,874</b>	<b>14,104</b>	<b>-230</b>				

### NSE DERIVATIVES TURNOVER

Rs. Crs	22-Nov	21-Nov	% Chg	FII's Contribution
INDEX FUTURES	13,131	13,217	-1%	19%
INDEX OPTIONS	566,001	391,569	45%	22%
<b>TOTAL INDEX</b>	<b>579,133</b>	<b>404,786</b>	<b>43%</b>	
STOCK FUTURES	48,161	52,199	-8%	31%
STOCK OPTIONS	37,363	38,606	-3%	35%
<b>TOTAL STOCKS</b>	<b>85,524</b>	<b>90,806</b>	<b>-6%</b>	

FII's contribution to the total Derivatives turnover

24%

25%

### DISCLAIMERS AND DISCLOSURES

LKP Sec. Ltd. (CIN-U67120MH1994PLC080039, www.lkpsc.com) and its affiliates are a full-fledged, brokerage and financing group. LKP was established in 1992 and is one of India's leading brokerage and distribution house. LKP is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). LKP along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds etc.

LKP hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on LKP for certain operational deviations in ordinary/routine course of business. LKP has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

LKP offers research services to clients. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by LKP and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

Research Analyst or his/her relative's financial interest in the subject company. (NO)

LKP or its associates may have financial interest in the subject company.

LKP or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (LKP) has not been engaged in market making activity for the subject company.

LKP or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report.

Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: (NO)

LKP or its associates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

LKP or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

LKP or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report.

Subject Company may have been client of LKP or its associates during twelve months preceding the date of distribution of the research report and LKP may have co-managed public offering of securities for the subject company in the past twelve months.

Research Analyst has served as officer, director or employee of the subject company: (NO)

LKP and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject LKP or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person.

Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

All trademarks, service marks and logos used in this report are trademarks or registered trademarks of LKP or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

All material presented in this report, unless specifically indicated otherwise, is under copyright to LKP. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of LKP